Ji SHI; Peixin SUN, Ye ZHANG, Bing YAO, Haozhe PIAO
BIOCELL, Vol.43, No.3, pp. 119-128, 2019, DOI:10.32604/biocell.2019.07577
Abstract Glioma is the most common primary malignant brain tumor with a poor survival rate. In recent years, no
significant progress has been made in the treatment of gliomas in contrast to the development of improved diagnosis
via molecular typing. Newcastle disease virus (NDV), a negative-stranded RNA virus that exhibits oncolytic activity,
has been investigated for its capacity to elicit antitumor activity in many types of cancers, including glioma. Therefore,
application of oncolytic viruses, such as NDV, as a new treatment strategy to specifically target aberrant signaling in
glioblastomas has brought new hope. For many years, More >